InvestorsHub Logo
Followers 226
Posts 5049
Boards Moderated 0
Alias Born 03/15/2010

Re: None

Tuesday, 09/01/2015 10:12:00 AM

Tuesday, September 01, 2015 10:12:00 AM

Post# of 194795
Creative Edge Nutrition, Inc. Update Letter to Shareholders
Marketwired

September 01, 2015: 09:00 AM ET

http://money.cnn.com/news/newsfeeds/articles/marketwire/1215180.htm

CEN Biotech Inc. has issued and served upon the Office of the Deputy Attorney General of Canada, its Notice of Intent to seek arbitration under Chapter 11 of the NAFTA (North American Free Trade Agreement). This service is being issued since the denial of its application under the MMPR was arbitrary and capricious and not based on any tangible evidence. Chapter 11 of the NAFTA allows investors an avenue for settlement of disputes that ensures equal treatment among all parties.

CEN Biotech Inc. is now in receipt of new factual information evidencing such an arbitrary and capricious denial of its license. Service and notice for arbitration was the appropriate next step to settle the losses its investors have suffered as a result of the MMPR program in Canada. The losses suffered by the company, its investors, and family and friends are immeasurable. Therefore, the company will seek all legal and dispute measures available to raise claim and recapture its losses.

The Notice is seeking an undisclosed, yet sizable amount based on the accumulated potential revenue of its fully completed and inspected medical marijuana manufacturing facility. The Company is seeking losses for the harm, suffering, and general damages pertaining to the inability to commence production of medical marijuana for the Canadian market patients.

CEN Biotech Inc. had applied for 600,000 kgs of medical marijuana annual capacity. Following this application and at the direction of the Canadian MMPR, the Company invested over ten million dollars building a world class production facility. This fully completed and inspected facility resides within one mile of an Ontario Police detachment, was built with Level 9 security protocols, and adheres to Canadian MMPR guidelines.

CEN Biotech Inc. will issue further statements as they become available, but will not answer questions in regards to litigation to ensure natural justice and procedural fairness is had to all parties involved.



$FITX